Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients

AIDS. 2004 Nov 5;18(16):2205-8. doi: 10.1097/00002030-200411050-00016.

Abstract

Data from 20 highly drug-experienced HIV-infected patients receiving tenofovir plus didanosine as part of a salvage regimen were analysed. At baseline, all but one patient harboured a virus bearing at least one nucleoside excision mutation (NEM); in 13 cases (65%) three or more NEM were detectable. After a median of 26 weeks of treatment, two patients (10%) selected the 65R mutation. These results support the hypothesis that NEM hinder the selection of this mutation.

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use*
  • Anti-HIV Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • DNA, Viral / analysis
  • Databases, Genetic
  • Didanosine / therapeutic use*
  • Drug Resistance, Multiple, Viral
  • Gene Deletion
  • Genotype
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV-1 / genetics*
  • Humans
  • Mutation
  • Organophosphonates / therapeutic use*
  • Tenofovir

Substances

  • Anti-HIV Agents
  • DNA, Viral
  • Organophosphonates
  • Tenofovir
  • Adenine
  • Didanosine